[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342901-105":59,"doc-detail-342901-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rpn1-a-pan-cancer-biomarker-and-disulfidptosis-regulator","RPN1 - a pan-cancer biomarker and disulfidptosis regulator","","RPN1’s relationship to disulfidptosis is investigated to clarify how this emerging cell-death modality operates beyond SLC7A11 dependence. The study tests the hypothesis that disulfidptosis is executed through cell skeleton breakdown, using flow cytometry, immunofluorescence, and western blot assays. Bioinformatics evaluates RPN1 expression across multiple solid tumors, its diagnostic power, survival associations, immune pathway enrichment, and links to anti-PD-L1 immunotherapy efficacy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rpn1-a-pan-cancer-biomarker-and-disulfidptosis-regulator/342901/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rpn1-a-pan-cancer-biomarker-and-disulfidptosis-regulator/342901.png","ImageObject",300,407,{"name":92,"@type":93},"Violet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main goal regarding RPN1 and disulfidptosis?","Question",{"text":112,"@type":113},"Determine the mechanism by which RPN1 induces disulfidptosis and assess whether RPN1 can serve as a pan-cancer biomarker.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the mechanism of RPN1-mediated disulfidptosis tested?",{"text":117,"@type":113},"The study hypothesizes that disulfidptosis is executed through cell skeleton breakdown and validates it using flow cytometry, immunofluorescence, and western blot.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports RPN1 as a pan-cancer biomarker and its clinical relevance?",{"text":121,"@type":113},"RPN1 shows robust mRNA expression across 16 solid tumors and exhibits significant diagnostic potential across 12 cancer types, with survival correlations and immune pathway enrichment reported.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342901,1790199818,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","RPN1: a pan-cancer biomarker and disulfidptosis regulator  \nXing Wang1,2, Hong-Quan Zhu2, Shi-Ming Lin2, Bao-Ying Xia2, Bo Xu1,3  \n1Department of General Surgery, The First Affiliated Hospital, Jinan University, Guangzhou, China; 2Department of General Surgery, Jiangmen Central Hospital, Jiangmen, China; 3Department of Thyroid Surgery, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, China  \nContributions: (I) Conception and design: X Wang, B Xu; (II) Administrative support: B Xu; (III) Provision of study materials or patients: X Wang, HQ Zhu; (IV) Collection and assembly of data: SM Lin, BY Xia; (V) Data analysis and interpretation: X Wang, HQ Zhu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.  \nCorrespondence to: Bo Xu, MD. Department of General Surgery, The First Affiliated Hospital, Jinan University, No. 613 Huangpu Avenue West, Tianhe District, Guangzhou 510630, China; Department of Thyroid Surgery, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, No. 1 Panfu Road, Yuexiu District, Guangzhou 510180, China. Email: [aabb97@163.com](aabb97@163.com).  \nBackground: Elevated expression of SLC7A11, in conjunction with glucose deprivation, has revealed disulfidptosis as an emerging cell death modality. However, the prevalence of disulfidptosis across tumor cell lines, irrespective of SLC7A11 levels, remains uncertain. Additionally, deletion of the ribophorin I (RPN1) gene imparts resistance to disulfidptosis, yet the precise mechanism linking RPN1 to disulfidptosis remains elusive. The aim of this study is to determine the mechanism of RPN1-induced disulfidptosis and to  \ndetermine the possibility of RPN1 as a pan-cancer marker.  \nMethods: We hypothesized the widespread occurrence of disulfidptosis in various tumor cells, and proposed that RPN1-mediated disulfidptosis may be executed through cell skeleton breakdown. Experimental validation was conducted via flow cytometry, immunofluorescence, and western blot techniques .  \nFurthermore, given RPN1’s status as an emerging cell death marker, we utilized bioinformatics to analyze its expression in tumor tissues, clinical relevance, mechanisms within the tumor microenvironment, and  \npotential for immunotherapy.  \nResults: Conducting experiments on breast cancer (MDA-MB-231) and lung cancer (A549) cell lines under glucose-starved conditions, we found that RPN1 primarily induces cell skeleton breakdown to facilitatedisulfidptosis. RPN1 demonstrated robust messenger RNA (mRNA) expression across 16 solid tumors, validated by data from 12 tumor types in the Gene Expression Omnibus (GEO) . Across 12 cancer types, RPN1 exhibited significant diagnostic potential, particularly excelling in accuracy for glioblastoma (GBM) .  \nElevated RPN1 expression in tumor tissues was found to correlate with improved overall survival (OS) in certain cancers [diffuse large B-cell lymphoma (DLBC) and thymoma (THYM)] but poorer prognosis in others [adrenocortical carcinoma (ACC), kidney chromophobe (KICH), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), and pancreatic adenocarcinoma (PAAD)] . RPN1 is enriched in immune-related pathways and correlates with immune scores in tumor tissues. In urothelial carcinoma (UCC), RPN1 demonstrates potential in predicting the efficacy of anti-programmed cell death ligand 1 (PD-L1)  \nimmune therapy.  \nConclusions: This study underscores RPN1’s role in facilitating disulfidptosis, its broad relevance as a  \npan-cancer biomarker, and its association with the efficacy of anti-PD-L1 immune therapy.  \nKeywords: Disulfidptosis; ribophorin I (RPN1); SLC7A11; anti-programmed cell death ligand 1 (anti-PD-L1);  \npan-cancer  \nSubmitted Apr 08, 2024. Accepted for publication May 15, 2024. Published online May 29, 2024.  \ndoi: 10.21037/tcr-24-581  \nView this article at: [https://dx.doi.org/10.21037/tcr-24-581](https://dx.doi.o","cbCaibk2MZ6H9pQP","https://ap.wps.com/l/cbCaibk2MZ6H9pQP","pdf",6678415,17,"English","# Background\n## Elevated SLC7A11 and glucose deprivation link to disulfidptosis\n## RPN1 deletion confers resistance; mechanism unclear\n# Methods\n## Hypothesis and experimental validation\n## Bioinformatics analyses in tumors and tumor microenvironment","[{\"question\":\"What is the study’s main goal regarding RPN1 and disulfidptosis?\",\"answer\":\"Determine the mechanism by which RPN1 induces disulfidptosis and assess whether RPN1 can serve as a pan-cancer biomarker.\"},{\"question\":\"How was the mechanism of RPN1-mediated disulfidptosis tested?\",\"answer\":\"The study hypothesizes that disulfidptosis is executed through cell skeleton breakdown and validates it using flow cytometry, immunofluorescence, and western blot.\"},{\"question\":\"What evidence supports RPN1 as a pan-cancer biomarker and its clinical relevance?\",\"answer\":\"RPN1 shows robust mRNA expression across 16 solid tumors and exhibits significant diagnostic potential across 12 cancer types, with survival correlations and immune pathway enrichment reported.\"}]","RPN1 - a pan-cancer biomarker and disulfidptosis regulator | PDF",1790048730,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9eaa0e276186ee668fccc000195fb1c.webp",983,1287,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb92f4fd408ccb536a4bc80958d27c66.webp",982,1286,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eca0252d397bba80adee96a70527b48a.webp",981,1284,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/070e9ee122344831bd206593f90b2c53.webp",980,1283]